Humanin & SS-31: Mitochondrial Peptides

Category: Protocols Type: Protocol Read Time: 16 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/humanin-ss31-protocol

Educational content only. Not medical advice. Humanin and SS-31 are emerging therapeutics with limited human safety data outside disease-specific clinical trials.

Overview

Cutting-edge longevity peptides targeting cellular energy. This guide covers mechanisms of action, current research status, dosing extrapolated from clinical trials, and stacking strategies with other longevity peptides.

Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP) encoded by the mitochondrial 16S rRNA gene — the same class of discovery that gave us MOTS-c. First identified in the brains of Alzheimer's patients who showed unexpected neuronal survival, Humanin is now studied as a systemic cytoprotective and metabolic regulator.

SS-31 (Szeto-Schiller-31, also known as Elamipretide or Bendavia) is a synthetic 4-amino-acid mitochondria-targeting peptide developed by Hazel Szeto and Peter Schiller. It is being investigated for FDA approval in specific mitochondrial diseases by Stealth BioTherapeutics.

Together, these peptides represent a class of "upstream" longevity interventions — targeting the mitochondria, the energy-producing engines whose decline is implicated in nearly every age-related disease.

Why Mitochondrial Health Matters

Mitochondria do more than make ATP. They are decision-making organelles that govern cellular fate.

Core Mitochondrial Functions:

• ATP production via oxidative phosphorylation
• Reactive oxygen species (ROS) regulation — a controlled source and target of oxidative stress
• Apoptosis control — release of cytochrome c initiates programmed cell death
• Calcium buffering and metabolic signaling
• Steroid and heme biosynthesis

Age-Related Mitochondrial Decline:

• Accumulated mtDNA damage from oxidative stress
• Cristae disorganization — the folded inner membrane that houses the electron transport chain becomes disordered
• Decreased respiratory capacity and lower maximum ATP output
• Excessive ROS leakage with reduced antioxidant capacity
• Impaired mitophagy — damaged mitochondria are not efficiently cleared

Intervening at the mitochondrial level is considered "upstream" because nearly every downstream hallmark of aging (cellular senescence, stem cell exhaustion, chronic inflammation) is influenced by mitochondrial function.

Humanin Mechanism

Humanin operates through multiple cytoprotective and metabolic pathways.

Primary Mechanisms:

1. Anti-apoptotic signaling — binds Bax and prevents its translocation to mitochondrial membranes, blocking cytochrome c release
2. STAT3 pathway activation — promotes pro-survival gene expression
3. Neuroprotection — extensively studied in Alzheimer's disease models, where it appears to protect neurons from amyloid-beta toxicity
4. Metabolic regulation — improves insulin sensitivity in preclinical models, influences glucose handling
5. Anti-inflammatory effects — modulates cytokine signaling

Humanin Variants:

• Native Humanin — wild-type 24-amino-acid sequence
• HNG (Humanin-G) — single amino acid substitution (Ser14→Gly) yielding a more potent and stable analog used in most research
• HNGF6A and other engineered variants in preclinical development

Age Correlation:

Circulating Humanin levels decline significantly with age. Long-lived individuals and centenarians tend to maintain higher levels, fueling interest in Humanin supplementation as a longevity intervention.

SS-31 Mechanism

SS-31 is a small synthetic tetrapeptide engineered specifically to localize to the inner mitochondrial membrane.

How It Works:

1. Cardiolipin binding — SS-31 selectively binds cardiolipin, a phospholipid uniquely concentrated in the inner mitochondrial membrane
2. Cristae stabilization — preserves the highly folded architecture that maximizes electron transport chain efficiency
3. ROS reduction — decreases mitochondrial superoxide production at its source rather than scavenging downstream
4. Improved respiratory chain coupling — restores efficient ATP synthesis in dysfunctional mitochondria
5. Cytochrome c protection — preserves the structural integrity that prevents pathological apoptosis

Regulatory Status:

SS-31 (Elamipretide) has received FDA Fast Track designation for several mitochondrial conditions, including Barth syndrome (a rare mitochondrial cardiomyopathy) and primary mitochondrial myopathy (PMM). It is not approved for general wellness or anti-aging use.

SS-31 Clinical Trial History

Stealth BioTherapeutics has run an extensive clinical program over the past decade.

Notable Trials:

• REPLY trial — Barth syndrome; mixed outcomes with signals of functional improvement
• MMPOWER series (MMPOWER, MMPOWER-2, MMPOWER-3) — primary mitochondrial myopathy; Phase 3 results were mixed and did not consistently meet primary endpoints
• TAZPOWER — Barth syndrome open-label and crossover study
• Cardiac ischemia/reperfusion trials — earlier indications largely deprioritized

Current Status:

Despite mixed late-stage outcomes, Elamipretide continues in development for specific rare mitochondrial diseases. FDA approval has been pursued multiple times for Barth syndrome with ongoing regulatory engagement. No approval for general anti-aging or wellness use exists.

Dosing Protocols

The dosing below is extrapolated from clinical trial literature and reports from research-chemical users. Rigorous human wellness dosing has not been established.

Reconstitution Notes:

• Both peptides are typically lyophilized; reconstitute with bacteriostatic water
• SS-31 is generally stable refrigerated for 2–4 weeks after reconstitution
• Humanin variants vary in stability — HNG is more stable than native Humanin

Cost Reality:

SS-31 at clinical trial doses (40 mg/day) is prohibitively expensive for most research users — often $1,000+ per month from reputable sources. Lower wellness-style dosing is more common in practice but lacks evidence.

Expected Outcomes

What user reports and preclinical data suggest — with significant caveats about evidence quality.

Weeks 2–4:

• Some users report subjective energy improvement
• Possible reduced post-exercise fatigue
• Anecdotal sleep quality changes

Weeks 4–8:

• Reported endurance improvements (theoretical, not validated outside disease populations)
• Possible improvements in lactate clearance markers
• Subjective cognitive clarity in some reports

Biomarkers Sometimes Tracked:

• Resting and exercise lactate
• VO2 max (in trained users)
• Heart rate variability (HRV)
• Standard mitochondrial panels (rarely available outside research settings)

Important caveat: Rigorous human efficacy data exists primarily in disease populations (Barth syndrome, PMM). The translation to healthy adults seeking longevity benefit is theoretical and unproven.

Side Effects & Safety

SS-31 (from clinical trials):

• Generally well-tolerated in trial populations
• Injection site reactions (most common)
• Headache (occasional)
• GI symptoms — nausea, mild stomach discomfort
• No significant long-term safety signals reported in trial follow-up

Humanin:

• Minimal human safety data — most studies are preclinical
• Theoretical concerns include excessive cytoprotective signaling (could affect normal apoptotic clearance)
• No established adverse event profile in healthy adults

Contraindications & Cautions:

• Pregnancy and breastfeeding
• Active malignancy (theoretical — anti-apoptotic effects may protect unhealthy cells)
• Concurrent investigational drug trials
• Children — not studied

What We DON'T Know

Honest accounting of the evidence gaps.

• Limited human data outside specific disease populations — most efficacy data for SS-31 comes from Barth syndrome and PMM; Humanin human data is even sparser
• Long-term safety is unknown — multi-year exposure data in healthy adults does not exist
• Optimal wellness dosing is unestablished — current dosing is extrapolated, not validated
• Sourcing purity is a major issue — these peptides have a documented high counterfeit rate in the research-chemical market
• Bioavailability and pharmacokinetics in healthy adults are poorly characterized
• No validated biomarkers for confirming target engagement in non-disease contexts
• Interaction with other longevity interventions (NAD+ precursors, senolytics, exercise) is theoretical

Stacking

Theoretical stacking strategies. None are validated by controlled human trials.

Humanin/SS-31 + MOTS-c

Another mitochondrial-derived peptide. Theoretical synergy through complementary mitochondrial pathways (MOTS-c regulates AMPK and metabolic homeostasis). No combination trials exist.

Humanin/SS-31 + NAD+ Precursors (NMN, NR)

NMN and NR boost cellular NAD+ levels, a critical mitochondrial cofactor. Pairing substrate support (NAD+) with structural/functional support (SS-31) is a popular theoretical stack.

• NMN: 500–1,000 mg oral daily
• NR: 300–600 mg oral daily

Humanin/SS-31 + Epithalon

Longevity stack combining telomerase activation (Epithalon) with mitochondrial protection. Both are highly speculative in healthy adults.

• Epithalon: 10 mg SC daily for 10-day cycles, quarterly

The Most Proven Mitochondrial Intervention: Exercise

Zone 2 cardio and high-intensity interval training (HIIT) remain the most validated mitochondrial biogenesis stimuli. Peptides should be considered adjunctive to — never a replacement for — structured exercise.

Cycling

Wellness Use (Extrapolated):

• 8–12 week cycles with 4–8 week off-periods is a common research-user pattern
• Avoids tachyphylaxis concerns and limits cumulative exposure of unknown long-term risk

Disease-Specific Clinical Protocols:

• Often ongoing/continuous in mitochondrial disease populations under physician supervision
• Trial protocols frequently dose daily for 6 months to multiple years

Practical Considerations:

• Track subjective and objective markers across each cycle
• Document any adverse effects
• Reassess after each cycle whether continuation is warranted

Frequently Asked Questions

Q: Is there a real anti-aging benefit in healthy adults? A: The honest answer is we don't know. Clinical efficacy has only been demonstrated (with mixed results) in specific mitochondrial diseases. Anti-aging benefit in healthy adults is theoretical and based on mechanism rather than outcome data.

Q: How does SS-31 compare to CoQ10 or Urolithin A? A: All three target mitochondrial function but through different mechanisms. CoQ10 supports the electron transport chain as a cofactor. Urolithin A promotes mitophagy. SS-31 stabilizes inner membrane architecture and reduces ROS at the source. CoQ10 and Urolithin A have stronger oral bioavailability and significantly more accessible safety profiles for general use.

Q: Can I stack these with NMN? A: Theoretically yes — NMN provides substrate (NAD+) while SS-31 and Humanin offer structural/functional support. There are no controlled trials confirming synergy in humans.

Q: How do I access SS-31 through a clinical trial? A: Search ClinicalTrials.gov for Elamipretide. Active trials typically require diagnosed mitochondrial disease (Barth syndrome, PMM, dry AMD in some studies). General-population enrollment is rare.

Q: Is sourcing reliable in the research-chemical market? A: SS-31 and Humanin have a documented high counterfeit rate. Demand independent third-party COAs (HPLC and mass spectrometry) before purchase. Many products sold as SS-31 fail purity testing.

Q: Is it worth the cost? A: At true clinical doses ($1,000+/month for SS-31), the cost-benefit ratio is poor for healthy adults given the lack of evidence. At lower wellness doses, you may be paying for sub-therapeutic exposure. Exercise, sleep, and zone 2 cardio remain better-validated mitochondrial interventions.

Q: Can these reverse age-related mitochondrial decline? A: Preclinical models show partial restoration of mitochondrial function. Whether this translates to meaningful longevity benefit in humans remains unproven.

Q: Will SS-31 ever get FDA approved? A: Approval is being actively pursued for Barth syndrome and related rare mitochondrial diseases. General anti-aging approval is not on any current regulatory pathway.

Related Content

• MOTS-c Mitochondrial Peptide Guide
• Epithalon Longevity Protocol
• NAD+ and NMN Guide
• Longevity Peptide Stack
• Reconstitution Cheat Sheet

Disclaimer: This content is for educational purposes only and is not medical advice. Humanin, HNG, and SS-31 (Elamipretide) are research compounds. SS-31 is in clinical development for specific mitochondrial diseases but is not FDA-approved for general use. These peptides are not approved for wellness, anti-aging, or performance use. Sourcing purity is a known issue in the research-chemical market. Consult a qualified healthcare provider before starting any peptide protocol.

References: Cohen P, et al. (Humanin discovery and metabolic studies). Szeto HH, Schiller PW (SS-peptide design and cardiolipin targeting). Stealth BioTherapeutics clinical program publications (MMPOWER, REPLY, TAZPOWER trials).

Source: https://peptides.nyc/learn/humanin-ss31-protocol